REQUEST A DEMO
Total
USD $0.00
Search more companies

Sanofi S.R.O. (Czech Republic)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Sanofi S.R.O. Profile Updated: March 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Sanofi-Aventis S.R.O. is a pharmaceutical company located in Prague, Czech Republic. The company has been operating since 1992 and offers a range of products and services. Their portfolio includes innovative drugs from Sanofi, over-the-counter medications, vaccines from Sanofi Pasteur, and medications for rare diseases from Sanofi Genzyme. Sanofi's logo can be found on every fifth medication used by Czech patients, and they manufacture half of the top-selling drugs, including popular ones like Paralen and Ibalgin. The company focuses on finding new, more effective, affordable, and patient-friendly treatment methods. They invest approximately five billion euros annually in research and development, with plans to increase this amount to six billion euros by 2020. Currently, their research teams are working on 50 projects and vaccines in clinical development, with the potential to introduce 15 new products to the market in the coming years. Sanofi offers highly innovative products, particularly for the treatment of diabetes, oncological diseases, cardiology, transplantation, and hemodialysis. They also provide a wide range of medications for the central nervous system, including epilepsy, insomnia, and schizophrenia treatments. Additionally, Sanofi's product portfolio includes medications for internal medicine, such as osteoporosis and rheumatoid arthritis, urological issues, antimalarials, pain relief, common cold, allergies, and more. The company's main goals include developing cutting-edge medications for the prevention and treatment of cardiovascular diseases. They currently have medications on the market for hypertension, heart failure, and products that reduce the risk of cardiovascular events, such as heart attacks, strokes, and cardiovascular death. Sanofi is also recognized for its advancements in the treatment of various types of cancer, particularly colorectal and breast cancer, as well as complications associated with chemotherapy in children with leukemia.

Headquarters
Generala Piky 430/26
Prague; The City of Prague; Postal Code: 16000

Contact Details: Purchase the Sanofi S.R.O. report to view the information.

Website: http://www.sanofi.cz

Basic Information
Total Employees:
Purchase the Sanofi S.R.O. report to view the information.
Outstanding Shares:
Purchase the Sanofi S.R.O. report to view the information.
Registered Capital:
Purchase the Sanofi S.R.O. report to view the information.
Financial Auditors:
Purchase the Sanofi S.R.O. report to view the information.
Incorporation Date:
December 13, 1991
Key Executives
Purchase this report to view the information.
Legal Representative
Purchase this report to view the information.
Legal Representative
Purchase this report to view the information.
Proxy
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Opella Healthcare Czech S.R.O.
100%
Company Performance
Financial values in the chart are available after Sanofi S.R.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
-12.12%
Total operating revenue
-12.12%
Operating profit (EBIT)
23.25%
EBITDA
48.95%
Net Profit (Loss) for the Period
-9.97%
Total assets
12.9%
Total equity
7.45%
Operating Profit Margin (ROS)
0.94%
Net Profit Margin
0.04%
Return on Equity (ROE)
-1.34%
Debt to Equity Ratio
-0.05%
Quick Ratio
0.04%
Cash Ratio
-0%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?